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OBJECTIVES The present study was designed to compare the absolute myocardial blood flow (MBF) after
intravenous dipyridamole infusion with that during dobutamine-atropine administration in
normal healthy male volunteers.
BACKGROUND Both safety and usefulness of dobutamine-atropine stress in myocardial perfusion imaging
have been reported. However, no information exists on whether the magnitude of hyperemia
achieved with dipyridamole and dobutamine-atropine is comparable.
METHODS Myocardial blood flow was measured with positron emission tomography and 15O-labeled
water in 20 healthy young men (23 6 3 years) 1) at baseline, 2) after dipyridamole infusion
(0.56 mg/kg over 4 min), and 3) during dobutamine (40 mg/kg/min) and atropine (0.25 to
1.0 mg) infusion.
RESULTS The MBF was significantly increased during dipyridamole infusion and during dobutamine–
atropine stress compared with at rest (4.33 6 1.23 and 5.89 6 1.58 vs. 0.67 6 0.16 ml/min/g,
respectively, p , 0.0001). Moreover, dobutamine-atropine infusion produced greater MBF
compared with dipyridamole (p 5 0.0011), while coronary vascular resistance did not differ
significantly after dipyridamole administration and during dobutamine-atropine infusion
(17.6 6 7.9 vs. 18.6 6 5.6 mm Hg/[ml/min/g], respectively).
CONCLUSIONS Near maximal coronary vasodilatation caused by dipyridamole is attainable using dobutamine
and atropine in young healthy volunteers. Dobutamine in conjunction with atropine is no less
effective than dipyridamole in producing myocardial hyperemia. (J Am Coll Cardiol 2001;37:
130–6) © 2001 by the American College of Cardiology
Exercise stress in conjunction with radionuclide perfusion
imaging is a well-established diagnostic approach for de-
tecting coronary artery disease (CAD) (1,2). However,
many patients are unable to physically perform an adequate
exercise for various reasons such as peripheral vascular
disease, pulmonary disease, orthopedic problem, old age and
physical conditioning. Consequently, pharmacological cor-
onary vasodilators including dipyridamole (3–5), adenosine
(3,6,7), or positive inotropic agents such as dobutamine
(8–13) and arbutamine (14) have emerged as effective
alternatives. Exercise or dobutamine alone produces less
increase in myocardial blood flow (MBF) than either
dipyridamole or adenosine (8,12,15,16). As a result, dobut-
amine is considered less effective as a pharmacological stress
agent for detecting coronary artery disease (17).
Atropine use in conjunction with dobutamine infusion
has been extensively utilized in pharmacological stress for
functional imaging (18–24). This approach has been intro-
duced in myocardial perfusion imaging, and its usefulness
and safety have been confirmed (25–28). However, no
information exists on whether the magnitude of hyperemia
achieved with dipyridamole and dobutamine-atropine is
comparable. The purpose of the present study was to
compare the absolute MBF (ml/min/g) after intravenous
(IV) dipyridamole infusion and that during dobutamine-
atropine administration using positron emission tomogra-
phy (PET) and 15O-labeled water in normal healthy
volunteers.
METHODS
Subjects. We studied 20 normal male volunteers with an
average age of 23 6 3 years (range 20 to 35 years). No
patient had a history of diabetes or hypertension. None of
the participants had a history of cardiovascular disease or
smoking. Entrance criteria included normal heart rate,
blood pressure (BP) and resting and stress electrocardio-
gram (ECG) and a low probability for CAD (29). The
investigative nature and potential risks of the study were
explained to all subjects. Each subject gave written informed
consent approved by the Kyoto University Ethics Committee.
PET imaging. All PET studies were performed after an
8-h fast. In addition, all volunteers were carefully instructed
to refrain from intake of caffeine-containing beverages or
foods within 24 h before the study.
The study protocol is shown in Figure 1. On the first day,
MBF was measured at rest and after dipyridamole infusion.
Each subject was positioned in the gantry of the PET
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camera (Advance, General Electric Medical Systems, Mil-
waukee, Wisconsin) with the aid of ultrasound. The char-
acteristics of this camera have been previously described
(30). The spatial resolution of the reconstructed clinical
PET images is ;8 mm in full-width half-maximum at the
center of the field of view, and the axial resolution is ;4 mm
(31). The subjects were lying supine in the PET scanner
with their arms out of the field of view. Heart rate, BP and
ECG were monitored continuously during the PET studies.
A 10-min transmission scan using two rotating 68Ge pin
sources was made for the attenuation correction. After a
transmission scan, subjects were requested to inhale
[15O]CO for 2 min. After inhalation, carbon monoxide was
allowed to combine with hemoglobin in red blood cells for
3 min before a 4-min static scan was started. During the
scan period, three blood samples were drawn at 2-min
intervals and radioactivity was measured. A 10-min period
was allowed for [15O]CO radioactivity decay before the flow
measurements. Flow was measured at rest and 3 min after
the end of IV administration of dipyridamole (0.56 mg/kg
body weight over 4 min). Approximately 740 MBq of
[15O]H2O was injected intravenously over 2 min and a
20-frame dynamic PET scan was performed for 6 min
consisting of 6 3 5-s, 6 3 15-s and 8 3 30-s frames. All
data were corrected for dead time, decay and photon
attenuation.
Within a week, the same scan was repeated during
infusion of the dobutamine and atropine. Two catheters
were inserted: one for dobutamine infusion and another for
blood sampling and infusion of atropine and [15O]H2O.
Dobutamine infusion was started at a dose of 5 mg/kg/min
followed by 10 mg/kg/min (3-min stages), increasing by
10 mg/kg/min every 3 min to a maximum of 40 mg/kg/min.
Atropine was administered in 0.25-mg splits at 1-min
intervals to a maximal dose of 1.0 mg in subjects not
achieving the target heart rate (85% of age-predicted max-
imal heart rate) (19). Subjects were asked to rate reactions or
symptoms on a scale from 0 (no complaint) to 10 (intoler-
able). If the score reached 6, atropine was not given to the
maximal dose even when the target heart rate was not
achieved. After atropine was given, [15O]H2O PET scan
was initiated. Subsequently, [15O]CO and transmission
scans were obtained as described above during infusion of
40 mg/kg/min of dobutamine.
Data analysis. The analysis of PET images was conducted
with an image analysis package (Dr. View; Asahi-Kasei,
Tokyo, Japan) and special dedicated software package (32).
The PET images including transmission images, [15O]CO
images, and [15O]H2O dynamic images were reoriented
into short-axis planes. Myocardial regions of interest
Abbreviations and Acronyms
BP 5 blood pressure
CAD 5 coronary artery disease
CVR 5 coronary vascular resistance
ECG 5 electrocardiogram
IV 5 intravenous
MBF 5 myocardial blood flow
PET 5 positron emission tomography
ROI 5 region of interest
Figure 1. Individual values of average myocardial blood flow (MBF) at rest, after dipyridamole infusion and during dobutamine-atropine infusion.
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(ROIs) were drawn in the anterior, lateral, inferior and
septal walls of a midventricular slice. Values of regional
MBF (ml/min/g) were calculated according to the previ-
ously published method using a single-compartment model
(33–35). This method has introduced a concept of the
water-perfusable tissue fraction to solve the problem of the
partial volume effect and cardiac wall motions. The water-
perfusable tissue fraction is defined as the fractional mass of
the tissue that is rapidly exchanging water within an ROI.
Thus, this represents the recovery coefficient of the myo-
cardial signal in the ROI. The water-perfusable tissue
fraction is determined from the kinetic model analysis.
Therefore, the method we have used to calculate MBF is
theoretically free from the partial volume effect. The arterial
input function was obtained from the left ventricular time-
activity curve using a previously validated method in which
corrections were made for the limited recovery of the left
ventricular ROI and the spillover from the myocardial
activities (36). In addition, a mean MBF value was obtained
for each study by averaging the values of the four myocardial
segments. To relate BP as an index of coronary driving
pressure to the hyperemic blood flow, an index of coronary
vascular resistance (CVR) (mm Hg/[ml/min/g]) was calcu-
lated by dividing the mean arterial pressure by blood flow
(5,37).
Statistical analysis. Statistics were calculated with a com-
mercially available personal computer software program
(StatView-J 5.0, Abacus Concepts, Berkeley, California).
Values are expressed as the mean 6 SD. The regional MBF
in four myocardial segments was compared by one-way
analysis of variance (ANOVA). Repeated measures
ANOVA was used to compare the groups with respect to
changes in hemodynamic data, MBF and CVR. The sta-
tistical significance of intergroup differences was assessed
using the Scheffe´ F test. A value of p , 0.05 was considered
statistically significant.
RESULTS
Hemodynamic responses. Hemodynamic data at rest,
after IV dipyridamole infusion and during IV adminis-
tration of dobutamine and atropine are shown in Table 1.
Diastolic and systolic BP increased during dobutamine-
atropine infusion compared with at rest or after dipyrid-
amole infusion (p , 0.0001). Heart rate increased sig-
nificantly after dipyridamole infusion (p , 0.0001) and
during dobutamine-atropine infusion (p , 0.0001).
Heart rate during dobutamine-atropine infusion was still
higher than during dipyridamole infusion (p , 0.0001).
Rate-pressure product increased significantly after dipyr-
idamole infusion (p 5 0.0004) and during dobutamine-
atropine infusion (p , 0.0001) compared with at rest
(9324 6 1864 and 24,609 6 2898 vs. 6386 6 1510 mm
Hg z beats/min, respectively).
Side effects during dipyridamole infusion and during
dobutamine-atropine administration. No serious side ef-
fects occurred during either of the two stress tests. In
dobutamine-atropine stress, every subject received maximal
dose of 40 mg/kg/min. No control subject reached target
heart rate by dobutamine alone. Therefore, atropine was
infused at least 0.25 mg in every subject. Mean dose of
atropine was 0.45 6 0.14 mg. Finally, 14 subjects (70%)
reached the target heart rate, whereas two subjects failed to
reach the target heart rate despite receiving the maximal
dose of dobutamine and atropine. Atropine was not given to
the maximal dose (1.0 mg) in four subjects without achiev-
ing the target heart rate, owing to palpitation and anxiety in
one subject, headache and anxiety in another subject, and
nausea in two subjects. Minor adverse reactions including
shortness of breath, palpitation, headache, anxiety, nausea
and dyspnea occurred in 14 subjects during dobutamine-
atropine infusion, but in only 7 subjects after dipyridamole
infusion (chi-square 5 4.91, p , 0.05) (Table 1). The
minor reactions of dobutamine-atropine infusion subsided
after the study without treatment. Even when the reactions
were not present, aminophylline (60 to 120 mg) was
administered in every subject at the end of dipyridamole
studies as part of our routine procedure. Minor reactions
associated with dipyridamole administration promptly dis-
appeared after aminophylline infusion.
MBF at rest, after dipyridamole infusion and during
dobutamine-atropine infusion. The regional values of
MBF measurements at rest, during dipyridamole infusion
and during dobutamine-atropine infusion are shown in
Table 2. No regional difference of MBF was noted at rest,
during dipyridamole infusion or during dobutamine-
atropine infusion.
Mean values of MBF and CVR at baseline, after IV
dipyridamole and during dobutamine-atropine infusion
are given for each subject in Table 1 and illustrated in
Figures 1 and 2. The MBF at rest ranged from 0.52 to
1.00 ml/min/g (average 0.67 6 0.16). During dipyridamole
infusion, MBF ranged from 1.72 to 6.20 ml/min/g (average
4.33 6 1.23). With IV infusion of dobutamine-atropine,
MBF ranged from 2.86 to 9.51 ml/min/g (average 5.89 6
1.58). Thus, mean MBF increased significantly with IV
dipyridamole (p , 0.0001) and with dobutamine-atropine
(p , 0.0001). Moreover, MBF during dobutamine-atropine
infusion was greater than during dipyridamole infusion (p 5
0.0011) (Fig. 1).
Mean CVR at rest, after dipyridamole infusion, and
during dobutamine-atropine infusion was 116.4 6 31.5,
17.6 6 7.9 and 18.6 6 5.6 mm Hg/(ml/min/g), respectively
(Fig. 2). The CVR decreased significantly with dipyrida-
mole (p , 0.0001) and with dobutamine-atropine (p ,
0.0001) compared with at rest. However, CVR did not
differ significantly after dipyridamole infusion and during
dobutamine-atropine stress despite the significant difference
in MBF.
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DISCUSSION
The present data demonstrated that dobutamine-atropine
stress produced greater increase in MBF than did dipyrid-
amole stress, whereas CVR did not differ significantly
during these pharmacological stress tests. These findings
indicate that dobutamine-atropine stress induces near max-
imal vasodilatation and that the difference of MBF during
these two pharmacological stress tests is caused by the
difference of coronary driving pressure.
The effect of dipyridamole and dobutamine on MBF.
Dipyridamole is a coronary artery vasodilator that increases
the extracellular concentration of adenosine by blocking its
cellular reuptake and metabolism (38). The standard dose of
dipyridamole (0.56 mg/kg over 4 min) can induce maximum
or near-maximal coronary vasodilatation in most subjects
(3,39). On the other hand, the mechanism of action of
dobutamine involves stimulation of beta-1, beta-2 and
alpha-1 receptors, resulting in positive inotropic and chro-
notropic effects (16). It is believed that dobutamine in-
creases myocardial oxygen demand, thereby increasing
MBF (16). Thus, dobutamine alone produces less increase
in MBF than either dipyridamole or adenosine (8).
Comparison with the previous studies. According to
previous studies, MBF and CVR after dipyridamole infu-
sion are 3.5 to ;5 ml/min/g and ;20 mm Hg/(ml/min/g)
using PET and 15O-labeled water in healthy volunteers of
similar age groups (4,5). The values of ;4 ml/min/g and
;18 mm Hg/(ml/min/g) obtained in the present study
were in agreement with previous findings. By contrast,
Krivokapich et al. (8) reported that the mean value of MBF
during infusion of 40 mg/kg/min of dobutamine alone was
2.25 ml/min/g in healthy volunteers using PET and [13N]
ammonia. To the best of our knowledge, this is the first
study to provide quantitative values of MBF during high
dose of dobutamine (40 mg/kg/min) and atropine infusion
in normal healthy volunteers. Unexpectedly, infusion of
dobutamine and atropine produced greater MBF than the
standard dose of dipyridamole infusion. Moreover, the
values of ;6 ml/min/g during infusion of dobutamine-
atropine is far above the values reported by Krivokapich et
al. (8). It is believed that this difference of MBF was partly
caused by the increased heat rate associated with atropine
infusion. The mean heart rate during the peak dobutamine
infusion was 110 beats/min (8), whereas the value during
the dobutamine-atropine stress in the current study was
163 beats/min. The difference of tracer for flow measure-
ments may be partly responsible for this significant differ-
ence. The MBF estimated by [13N] ammonia tends to be
lower than that by 15O-labeled water (10).
According to previous reports, dobutamine- or exercise-
induced increases in MBF are proportional to cardiac work
(10,12,15). In the current study, the average MBF increased
8.8-fold with dobutamine-atropine infusion, whereas rate-
pressure product increased only four-fold. Thus, the change
Table 2. Regional Myocardial Blood Flow at Rest and During
Pharmacological Stress
Region
Myocardial Blood Flow (ml/min/g)
Rest Dipyridamole
Dobutamine-
Atropine
Anterior 0.68 6 0.21 4.39 6 1.37 5.89 6 1.68
Lateral 0.66 6 0.19 4.38 6 1.20 5.85 6 1.57
Inferior 0.64 6 0.16 4.27 6 1.25 5.88 6 1.53
Septal 0.69 6 0.17 4.30 6 1.30 5.96 6 1.80
Figure 2. Individual values of average coronary vascular resistance (CVR) at rest, after dipyridamole infusion and during dobutamine-atropine infusion.
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of MBF due to dobutamine-atropine was markedly greater
than that of rate-pressure product, suggesting the presence
of coronary vasodilatation effect when atropine and dobut-
amine were infused together. In fact, CVR during
dobutamine-atropine infusion and after dipyridamole infu-
sion did not differ significantly (Fig. 2). The difference of
MBF during the two different myocardial stress tests is
considered to be caused simply by the difference of coronary
driving pressure. The physiological explanation for coronary
vasodilatation effect of dobutamine-atropine infusion can-
not be provided by the current study. The increase of MBF
obtained by atropine may be caused by the increase of heart
rate and consequently the myocardial oxygen demand. This
sort of active hyperemia may be induced by accumulation of
metabolites and certain vasoactive agents, particularly aden-
osine. For this issue, further studies are needed.
Clinical implications of dobutamine-atropine stress.
Minor reactions appeared more frequently in dobutamine-
atropine stress than in dipyridamole stress. In terms of
symptoms and reactions, dipyridamole may be recom-
mended as a pharmacological stress agent. As is suggested
elsewhere (16), patients who cannot exercise and who are
not good candidates for dipyridamole or adenosine because
of a history of chronic obstructive pulmonary disease,
asthma or high-degree atrioventricular block will be good
candidates for dobutamine-atropine stress. Other candi-
dates include patients who took caffeine or used medications
containing theophylline before a dipyridamole or adenosine
myocardial perfusion imaging. In addition, one of the
advantages of dobutamine over the vasodilator agents is the
ability to assess the ischemic threshold with dobutamine.
Moreover, the current study demonstrated that dobutamine
in conjunction with atropine produced greater increase in
MBF compared with dipyridamole. Thus, dobutamine-
atropine has a potential to surpass dipyridamole or adeno-
sine in producing flow disparity between myocardial regions
supplied by normal and stenotic arteries. The present theory
is in agreement with the findings by Levine et al. (40), who
showed that the size of myocardial perfusion defects in-
duced by dobutamine was larger than that induced by
dipyridamole in patients with CAD.
Conclusions. High doses of dobutamine with atropine
produced greater MBF than did the standard dose of
dipyridamole and without a significant difference in CVR.
These data suggest that near maximal coronary vasodilata-
tion caused by dipyridamole is attainable using dobutamine
and atropine in healthy young men. Dobutamine in com-
bination with atropine is considered no less effective than
dipyridamole for producing myocardial hyperemia.
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